emavusertib,ibrutinib
janssen,abbvie,curis
['ibru', 'lymphoma', 'emavusertib', 'curis']
curis at asco! we are presenting for the first time initial combination data from takeaim lymphoma, the use of emavusertib combined with ibrutinib in patients with relapsed or refractory hematologic malignancies, saturday 8:00-11:00am ct, abs #7575. #cris #asco22 #takeaim
NASDAQ: CRIS